| Followers | 832 |
| Posts | 119964 |
| Boards Moderated | 17 |
| Alias Born | 09/05/2002 |
Sunday, June 13, 2010 6:55:31 AM
Who’s Who in All-Oral HCV Programs
All five of these all-oral programs include a protease inhibitor (PI), which has proved to be the most effective drug class at reducing HCV viral load quickly. In two of the five programs (Roche and IDIX), the second drug is a nucleoside polymerase inhibitor (NI); in two of the programs (VRTX and GILD), the second drug is a non-nucleoside polymerase inhibitor (NNI); in one program (Bristol-Myers Squibb), the second drug is an NS5A inhibitor.
Among these five programs, only the one from IDIX has qD dosing and activity against multiple HCV genotypes. On the other had, the IDIX program is the least advanced of the five—the two drugs (IDX184 and IDX320) have not yet been tested together in HCV patients or healthy volunteers.
Source: IDIX webcast at Jefferies conference (10-Jun-2010)
All five of these all-oral programs include a protease inhibitor (PI), which has proved to be the most effective drug class at reducing HCV viral load quickly. In two of the five programs (Roche and IDIX), the second drug is a nucleoside polymerase inhibitor (NI); in two of the programs (VRTX and GILD), the second drug is a non-nucleoside polymerase inhibitor (NNI); in one program (Bristol-Myers Squibb), the second drug is an NS5A inhibitor.
Among these five programs, only the one from IDIX has qD dosing and activity against multiple HCV genotypes. On the other had, the IDIX program is the least advanced of the five—the two drugs (IDX184 and IDX320) have not yet been tested together in HCV patients or healthy volunteers.
Source: IDIX webcast at Jefferies conference (10-Jun-2010)
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
